The widening adjusted loss and tiny revenue base suggest PAVmed remains a story stock dependent on Lucid's Medicare coverage catalyst and Veris's FDA submission. The S-3 shelf filed 24 days prior adds dilution risk. Monitor the upcoming CMS draft coverage policy for EsoGuard — positive decision could transform Lucid's revenue trajectory and reduce cash burn concerns.
Price Chart
Executive Summary
PAVmed reported Q1 2026 revenue of $22K (up from $8K YoY) but GAAP net loss attributable to common stockholders widened to $7.0M ($(4.42)/share) from a $17.7M gain in Q1 2025, driven by non-cash fair value changes and preferred stock dividends. The company highlighted Lucid's $1.3M EsoGuard revenue and a strengthened balance sheet ($6.5M cash vs $1.5M at year-end), but the core operating loss and tiny revenue base remain concerning. The prior S-3 shelf registration (April 2026) adds overhang risk.
Key Financial Metrics
Key Facts
- Q1 2026 revenue was $22,000, up from $8,000 in Q1 2025 but still negligible for a $77M market cap company
- GAAP net loss attributable to common stockholders was $7.0M, or $(4.42) per diluted share, vs income of $17.7M in Q1 2025
- Non-GAAP adjusted loss was $1.9M ($(1.17)/share), worsening from $0.9M loss in Q1 2025
- Cash and cash equivalents improved to $6.5M from $1.5M at Dec 31, 2025, partly from Lucid's $17M public offering
- Lucid Diagnostics recognized $1.3M in EsoGuard revenue and processed 3,177 tests in Q1 2026
- S-3 shelf registration filed April 2026 registers 9.23M shares for resale, creating overhang
- Operating expenses rose to $8.1M from $5.5M YoY, driven by stock-based and stock-issued expenses
Financial Impact
Q1 2026 GAAP net loss of $7.0M vs prior-year income of $17.7M; non-GAAP adjusted loss of $1.9M vs $0.9M; cash burn remains significant at ~$5M/quarter operating loss
Risk Factors
- S-3 shelf registration creates overhang of 9.23M shares for resale, potentially pressuring stock
- Cash runway limited to ~$6.5M at current burn rate, requiring additional financing before catalysts materialize
- Lucid's Medicare coverage decision is binary and uncertain; delay or denial would severely impact PAVmed's valuation
- Veris implantable monitor is pre-FDA submission, with no near-term revenue visibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023352 |
| Document: form8-k.htm | 0001493152-26-023352 |
| Document: 0001493152-26-023352-index-headers.html | 0001493152-26-023352 |
| Document: 0001493152-26-023352-index.html | 0001493152-26-023352 |
| Document: 0001493152-26-023352.txt | 0001493152-26-023352 |
| 8-K Data (Synthetic) | 0001493152-26-023352 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13G/A | $2.17 | awaiting T+60 | — | $2.26 (+4.15%) |
Oct 22, 2026 4d ago | 8-K | $2.17 | awaiting T+60 | — | $2.26 (+4.15%) |
May 15, 2026 23w ago | 8-K | $6.53 $4.71 | ▲ +27.87% | ▲ +32.39% | $2.26 (+65.39%) |
Apr 20, 2026 27w ago | S-3 | $9.15 $6.02 | ▼ −34.17% | ▼ −41.07% | $2.26 (−75.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers